Development of Novel Monocarboxylate Transporter Inhibitors as Potential Anticancer Agents
2019-04
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Development of Novel Monocarboxylate Transporter Inhibitors as Potential Anticancer Agents
Authors
Published Date
2019-04
Publisher
Type
Thesis or Dissertation
Abstract
The metabolic phenotype of cancer cells is dependent on the differential oxygen and nutrient distribution in the tumor microenvironment. These diminishing resources coupled with increased energetic and biosynthetic demands of tumor cells further encourage the upregulation of glycolysis with overexpression of related enzymes and transporters. This shift towards a more glycolytic character results in a disruption of the intracellular pH as the cell rapidly becomes more acidic. The accumulation of acidic byproducts like lactic acid requires new strategies to maintain cellular homeostasis resulting in the overexpression of transporters. These extracellular acidic byproducts are taken up by neighboring cells and are utilized for oxidative phosphorylation (OxPhos). Cancer cells often switch between glycolysis and OxPhos to meet the energy demands, termed as metabolic plasticity, which is driven by a necessity to avoid conditions that would induce apoptosis. For this reason, cancer cells express proton coupled monocarboxylate transporters 1-4 (MCT1-4). Specifically, these transporters have been found to be expressed in the most aggressive tumors and ultimately been linked to poor patient outcome. Hence, this transporter can be targeted for therapeutic intervention to treat a wide variety of cancers. One well known MCT1 inhibitor α-cyano-4-hydroxycinnamic acid (CHC) has been traditionally used to study the functions of these transporters and it has been found to reduce tumor growth in mouse xenograft models. The therapeutic potential of CHC is hindered by its lack of efficacy at low concentrations and very high dose requirement for significant anticancer efficacy in vivo. In this regard, we have modified the CHC template with alkyl and aryl silyl substitutions and also introduced nitric oxide donors. These structural modifications have resulted novel candidate compounds which exhibit potent MCT1 and MCT4 inhibition and higher cell proliferation inhibition on several cancer cell lines. These drug candidates have also been evaluated for their effects on glycolytic and mitochondrial metabolic parameters. These studies have shown that all the lead derivatives have significant effects on both metabolic processes. Further in vivo preclinical evaluation of lead candidate compounds indicate that these compounds are generally well tolerated in healthy mice and exhibit growth inhibition in MCT1 and MCT4 expressing tumor models.
Description
University of Minnesota Ph.D. dissertation. April 2019. Major: Integrated Biosciences. Advisor: Venkatram Mereddy. 1 computer file (PDF); xxv, 289 pages.
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Nelson, Grady. (2019). Development of Novel Monocarboxylate Transporter Inhibitors as Potential Anticancer Agents. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/220585.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.